Hot Topic: Options in Advanced Skin Squamous Cell Carcinoma
This session will review the a growing clinical problem with staging, treatment and survival approaches of cutaneous squamous cell carcinoma.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.
Upon completion of this activity, participants should be able to do the following:
Review the indications for adjuvant radiation in high risk cSCC.
Identify evidence base for benefit of adjuvant RT.
Demonstrate techniques of IMRT and planning considerations.
Outline considerations for identifying appropriate cSCC candidates for surgical versus non-surgical management.
Identify staging options for advanced cSCC to include the role of sentinel node biopsy.
Discuss primary surgical resection options to include MOHS Micrographic Surgery and wide excision.
Review current approved systemic therapy in cSCC.
Discuss emerging strategies under clinical investigation in the curative setting.
Consider systemic treatment paradigms in solid organ transplant patients with cSCC.
Identify groups of immunosuppressed patients who are at higher risk for non-melanoma skin cancers.
Describe topical and systemic agents used to reduce the frequency of non-melanoma skin cancer in higher risk patients.
Cecelia Schmalback, MD, MSc, FACS is employed by Temple Health and has no financial relationships with a commercial interest.
Shlomo Koyfman, MD, is employed by the Cleveland Clinic and has research grants with Bristol Myers Squibb and Merck and is on the advisory board of Castle Biosciences, Merck and Regeneron.
Jessica Geiger, MD, is employed by the Cleveland Clinic Cancer Center and has no financial relationships with a commercial interest.
Anne Chang, MD is employed by Stanford University and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.